1,147
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Development of microbeads of chicken yolk antibodies against Clostridium difficile toxin A for colonic-specific delivery

, , , , , , & show all
Pages 1940-1947 | Received 07 Jan 2015, Accepted 21 Feb 2015, Published online: 23 Mar 2015

References

  • Al-Nassir WN, Sethi AK, Li Y, et al. (2008). Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403–6
  • Anosova NG, Brown AM, Li L, et al. (2013). Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters. J Med Microbiol 62:1394–404
  • Atyabi F, Inanloo K, Dinarvand R. (2005). Bovine serum albumin–loaded pectinate beads as colonic peptide delivery system: preparation and in vitro characterization. Drug Deliv 12:367–75
  • Barra-Carrasco J, Olguín-Araneda V, Plaza-Garrido A, et al. (2013). The Clostridium difficile exosporium cysteine (CdeC)-rich protein is required for exosporium morphogenesis and coat assembly. J Bacteriol 195:3863–75
  • Chaparro-Rojas F, Mullane KM. (2013). Emerging therapies for Clostridium difficile infection – focus on fidaxomicin. Infect Drug Resist 6:41–53
  • DuPont HL. (2011). The search for effective treatment of Clostridium difficile infection. N Engl J Med 364:473–5
  • Eaton SR, Mazuski JE. (2013). Overview of severe Clostridium difficile infection. Crit Care Clin 29:827–39
  • Freeman J, Stott J, Baines SD, et al. (2005). Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 56:988–9
  • Genisyuerek S, Papatheodorou P, Guttenberg G, et al. (2011). Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Mol Microbiol 79:1643–54
  • Guo G, Xing P, Liu H, et al. (2013). The expression of C. difficile toxin A C-terminal domain and preparation of IgY antibody. J Militar Med 196:676–80
  • Hansen P, Scoble JA, Hanson B, et al. (1998). Isolation and purification of immunoglobulins from chicken eggs using thiophilic interaction chromatography. J Immunol Methods 215:1–7
  • Hawkey PM, Marriott C, Liu WE, et al. (2013). Molecular epidemiology of Clostridium difficile infection in a major Chinese hospital: an underrecognized problem in Asia? J Clin Microbiol 51:3308–13
  • Kelly CP, Kyne L. (2011). The host immune response to Clostridium difficile. J Med Microbiol 60:1070–9
  • Kink JA, Williams JA. (1998). Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018–25
  • Koenigsknecht MJ, Young VB. (2013). Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs. Curr Opin Gastroenterol 29:628–32
  • Lima AA, Lyerly DM, Wilkins TD, et al. (1988). Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 56:582–8
  • Lowy I, Molrine DC, Leav BA, et al. (2010). Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205
  • O'Donoghue C, Kyne L. (2011). Update on Clostridium difficile infection. Curr Opin Gastroenterol 27:38–47
  • Ramasamy T, Ruttala HB, Shanmugam S, et al. (2013). Eudragit-coated aceclofenac-loaded pectin microspheres in chronopharmacological treatment of rheumatoid arthritis. Drug Deliv 20:65–77
  • Rao K, Micic D, Chenoweth E, et al. (2013). Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 61:1738–42
  • Roberts A, McGlashan J, Al-Abdulla I, et al. (2011). Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection. Infect Immun 80:875–82
  • Søes LM, Holt HM, Böttiger B, et al. (2013). Risk factors for Clostridium difficile infection in the community: a case–control study in patients in general practice, Denmark, 2009–2011. Epidemiol Infect 27:1–12
  • Tian JH, Fuhrmann SR, Kluepfel-Stahl S, et al. (2012). A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249–58
  • Tsai SW, Yu DS, Tsao SW, et al. (2013). Hyaluronan-cisplatin conjugate nanoparticles embedded in Eudragit S100-coated pectin/alginate microbeads for colon drug delivery. Int J Nanomed 8:2399–407
  • Voelker R. (2012). Study: vast majority of C. difficile infections occur in medical settings. JAMA 307:1356

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.